Trxade Group (NASDAQ:MEDS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.08) by 62.5 percent. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.
After FDA Rejection, Spectrum Shelves Development On Poziotinib
The FDA has granted a Complete Response Letter (CRL) to Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) marketing application seeking approval for poziotinib…
